ABIVAX (ABVX) investor relations material

Pipeline and development milestones

• Obefazimod is in pivotal Phase 3 for ulcerative colitis (UC) and Phase 2b for Crohn's disease (CD), with topline UC induction data in July 2025 and maintenance data in June 2026.

• Combination therapy candidates for UC are under evaluation, with a decision expected by year-end 2026.

• Selection of a follow-on compound from the miR-124 library is planned for 2026.

• Phase 2b CD induction topline results are expected in mid-2027.

Market opportunity and positioning

• Worldwide IBD sales are forecasted to reach ~$41B by 2032, with UC driving ~70% of US growth.

• Obefazimod targets a US patient population of up to 1.3M across UC and CD, with potential to become a future standard of care.

• Recent market research indicates obefazimod could penetrate first-line advanced therapy and become a market leader.

Mechanism of action and scientific rationale

• Obefazimod is an oral small molecule that selectively enhances miR-124, a physiological anti-inflammatory microRNA.

• It restores immune balance in UC by reducing inflammatory cytokines (IL-17, IL-6, IL-23, TNFα) and stabilizing Th17 cells.

• Clinical data confirm increased miR-124 expression in blood and colon tissue, with significant reductions in IL-17A and IL-6.